Pineal Gland Tumor Microenvironment.
ATRX
BRAF
DICER1
DROSHA
Germ cell tumors
Germinomas
Gliomas
Hypomethylation
Isocitrate dehydrogenase
KBTBD4
Microenvironment
Pineal gland
Pineal parenchymal tumors
Pineoblastomas
Pineocytomas.
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
29
6
2021
pubmed:
1
1
2020
medline:
2
7
2021
Statut:
ppublish
Résumé
A wide and heterogeneous variety of tumors develop from the pineal gland. Pineal parenchymal tumors, germ cell tumors, and glial tumors represent most of them. The molecular profiles and tumor microenvironment play a key role in the development and progression of pineal gland tumors. Consequently, they represent important factors that may determine the efficacy of the different treatment modalities and the clinical outcome. Current literature is scarce regarding the microenvironment research of pineal gland tumors. Here, we review the cellular and molecular profile of the pineal gland tumor microenvironment.
Identifiants
pubmed: 34185290
doi: 10.1007/978-3-030-59038-3_8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-150Références
Choque-Velasquez J, Resendiz-Nieves J, Jahromi BR, et al (2019) Extent of resection and long-term survival of pineal region tumors in Helsinki neurosurgery. World Neurosurg. Published online 29 July 2019
Mottolese C, Beuriat PA, Szathmari A (2015) Pineal tumours: experience of the French National Register and the Lyon School, results and considerations. Neuro-Chirurgie 61(2–3):223–235. https://doi.org/10.1016/j.neuchi.2014.02.006
doi: 10.1016/j.neuchi.2014.02.006
pubmed: 24933478
Shibui S, Nomura K (2009) Statistical analysis of pineal tumors based on the data of Brain Tumor Registry of Japan. Prog Neurol Surg 23:1–11. https://doi.org/10.1159/000210049
doi: 10.1159/000210049
pubmed: 19329857
Al-Hussaini M, Sultan I, Abuirmileh N, Jaradat I, Qaddoumi I (2009) Pineal gland tumors: experience from the SEER database. J Neuro-Oncol 94(3):351–358. https://doi.org/10.1007/s11060-009-9881-9
doi: 10.1007/s11060-009-9881-9
Carr C, O’Neill BE, Hochhalter CB, Strong MJ, Ware ML (2019) Biomarkers of Pineal Region tumors: a review. Ochsner J 19(1):26–31. https://doi.org/10.31486/toj.18.0110
doi: 10.31486/toj.18.0110
pubmed: 30983898
pmcid: 6447205
Nakazato Y, Jouvet A, Scheithauer BW (2006) Pineocytoma. In: WHO classification of tumors of the central nervous system, 4th edn. World Health Organization, pp 121–122
Nakazato Y, Jouvet A, Scheithauer BW (2006) Pineoblastoma. In: WHO classification of tumours of the central nervous system, 4th edn. World Health Organization, pp 126–127
Nakazato Y, Jouvet A, Scheithauer BW (2006). Pineal parenchymal tumours of intermediate differentiation. In: WHO classification of tumours of the central nervous system, 4th edn. World Health Organization, pp 124–125
Osborn AG, Salzman KL, Thurnher MM, Rees JH, Castillo M (2012) The new World Health Organization classification of central nervous system tumors: what can the neuroradiologist really say? AJNR Am J Neuroradiol 33(5):795–802. https://doi.org/10.3174/ajnr.A2583
doi: 10.3174/ajnr.A2583
pubmed: 21835942
pmcid: 7968804
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
Choque-Velasquez J, Resendiz-Nieves JC, Jahromi BR, et al (2018) Pineal parenchymal tumors of intermediate differentiation: a long-term follow-up study in Helsinki neurosurgery. World neurosurg. Published online 1 Nov 2018
Chatterjee D, Lath K, Singla N, Kumar N, Radotra BD (2019) Pathologic prognostic factors of pineal parenchymal tumor of intermediate differentiation. Appl Immunohistochem Mol Morphol 27(3):210–215. https://doi.org/10.1097/PAI.0000000000000565
doi: 10.1097/PAI.0000000000000565
pubmed: 28800009
Verma A, Epari S, Bakiratharajan D et al (2019) Primary pineal tumors - unraveling histological challenges and certain clinical myths. Neurol India 67(2):491–502. https://doi.org/10.4103/0028-3886.258045
doi: 10.4103/0028-3886.258045
pubmed: 31085866
Choque-Velasquez J, Resendiz-Nieves JC, Jahromi BR et al (2019) Pineoblastomas: a long-term follow up study of three cases in Helsinki neurosurgery. Interdiscip Neurosurg 18:100477. https://doi.org/10.1016/j.inat.2019.100477
doi: 10.1016/j.inat.2019.100477
Sato K, Kubota T (2009) Pathology of pineal parenchymal tumors. Prog Neurol Surg 23:12–25. https://doi.org/10.1159/000210050
doi: 10.1159/000210050
pubmed: 19329858
Snuderl M, Kannan K, Pfaff E et al (2018) Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nat Commun 9(1):2868. https://doi.org/10.1038/s41467-018-05029-3
doi: 10.1038/s41467-018-05029-3
pubmed: 30030436
pmcid: 6054684
de Kock L, Sabbaghian N, Druker H et al (2014) Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol 128(4):583–595. https://doi.org/10.1007/s00401-014-1318-7
doi: 10.1007/s00401-014-1318-7
pubmed: 25022261
pmcid: 4381868
Lee JC, Mazor T, Lao R et al (2019) Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathol 137(5):851–854. https://doi.org/10.1007/s00401-019-01990-5
doi: 10.1007/s00401-019-01990-5
pubmed: 30877433
pmcid: 6483828
Choque-Velasquez J, Resendiz-Nieves JC, Jahromi BR et al (2019) Pineocytomas: a long-term follow up study of four cases in Helsinki neurosurgery. J Case Rep Med 8(1):5–5
doi: 10.25149/case-reports.v8i1.162
Parikh KA, Venable GT, Orr BA et al (2017) Pineoblastoma-the experience at St. Jude Children’s Research Hospital. Neurosurgery 81(1):120–128. https://doi.org/10.1093/neuros/nyx005
doi: 10.1093/neuros/nyx005
pubmed: 28327927
Sabbaghian N, Hamel N, Srivastava A, Albrecht S, Priest JR, Foulkes WD (2012) Germline DICER1 mutation and associated loss of heterozygosity in a pineoblastoma. J Med Genet 49(7):417–419. https://doi.org/10.1136/jmedgenet-2012-100898
doi: 10.1136/jmedgenet-2012-100898
pubmed: 22717647
Kumar MS, Pester RE, Chen CY et al (2009) Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 23(23):2700–2704. https://doi.org/10.1101/gad.1848209
doi: 10.1101/gad.1848209
pubmed: 19903759
pmcid: 2788328
Martinez H, Nagurney M, Wang Z, et al (2019) ATRX mutations in pineal parenchymal Tumors of intermediate differentiation. J Neuropathol Exp Neurol. Published online 27 May 2019. https://doi.org/10.1093/jnen/nlz050
Gittleman H, Cioffi G, Vecchione-Koval T et al (2019) Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. J Neuro-Oncol 143(2):251–260. https://doi.org/10.1007/s11060-019-03173-4
doi: 10.1007/s11060-019-03173-4
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, revised 4th edn. World Health Organization
Jennings MT, Gelman R, Hochberg F (1985) Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 63(2):155–167. https://doi.org/10.3171/jns.1985.63.2.0155
doi: 10.3171/jns.1985.63.2.0155
pubmed: 2991485
Fukushima S, Yamashita S, Kobayashi H et al (2017) Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. Acta Neuropathol 133(3):445–462. https://doi.org/10.1007/s00401-017-1673-2
doi: 10.1007/s00401-017-1673-2
pubmed: 28078450
Sato K, Takeuchi H, Kubota T (2009) Pathology of intracranial germ cell tumors. In: Pineal Region tumors. KARGER, pp 59–75. https://doi.org/10.1159/000210053
Schmoll HJ, Souchon R, Krege S et al (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15(9):1377–1399. https://doi.org/10.1093/annonc/mdh301
doi: 10.1093/annonc/mdh301
pubmed: 15319245
Kyritsis AP (2010) Management of primary intracranial germ cell tumors. J Neuro-Oncol 96(2):143–149. https://doi.org/10.1007/s11060-009-9951-z
doi: 10.1007/s11060-009-9951-z
Schmoll HJ, Souchon R, Krege S et al (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15(9):1377–1399. https://doi.org/10.1093/annonc/mdh301
doi: 10.1093/annonc/mdh301
pubmed: 15319245
Gonzalez-Exposito R, Merino M, Aguayo C (2016) Molecular biology of testicular germ cell tumors. Clin Transl Oncol 18(6):550–556. https://doi.org/10.1007/s12094-015-1423-7
doi: 10.1007/s12094-015-1423-7
pubmed: 26482724
Roelofs H, Mostert MC, Pompe K et al (2000) Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol 157(4):1155–1166. https://doi.org/10.1016/S0002-9440(10)64631-7
doi: 10.1016/S0002-9440(10)64631-7
pubmed: 11021820
pmcid: 1850173
Dorssers LCJ, Gillis AJM, Stoop H et al (2019) Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development. Br J Cancer 120(4):444–452. https://doi.org/10.1038/s41416-019-0381-1
doi: 10.1038/s41416-019-0381-1
pubmed: 30739914
pmcid: 6461884
Díez-Torre A, Silván U, Díaz-Núñez M, Arechaga J (2010) The role of microenvironment in testicular germ cell tumors. Cancer Biol Ther 10(6):529–536. https://doi.org/10.4161/cbt.10.6.13227
doi: 10.4161/cbt.10.6.13227
pubmed: 20855948
Willis SN, Mallozzi SS, Rodig SJ et al (2009) The microenvironment of germ cell tumors Harbors a prominent antigen-driven humoral response. J Immunol 182(5):3310–3317. https://doi.org/10.4049/jimmunol.0803424
doi: 10.4049/jimmunol.0803424
pubmed: 19234230
Takami H, Fukushima S, Aoki K, et al (2019) Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance. Neuropathol Appl Neurobiol. Published online 29 July 2019:nan.12570. https://doi.org/10.1111/nan.12570
Siska PJ, Johnpulle RAN, Zhou A et al (2017) Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. OncoImmunology 6(4):e1305535. https://doi.org/10.1080/2162402X.2017.1305535
doi: 10.1080/2162402X.2017.1305535
pubmed: 28507813
pmcid: 5414873
Shah S, Ward JE, Bao R, Hall CR, Brockstein BE, Luke JJ (2016) Clinical response of a patient to anti-PD-1 immunotherapy and the immune landscape of testicular germ cell tumors. Cancer Immunol Res 4(11):903–909. https://doi.org/10.1158/2326-6066.CIR-16-0087
doi: 10.1158/2326-6066.CIR-16-0087
pubmed: 27638840
pmcid: 5104156
Cierna Z, Mego M, Miskovska V et al (2016) Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol 27(2):300–305. https://doi.org/10.1093/annonc/mdv574
doi: 10.1093/annonc/mdv574
pubmed: 26598537
Liu B, Arakawa Y, Yokogawa R et al (2018) PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. PLOS ONE 13(4):e0194594. https://doi.org/10.1371/journal.pone.0194594
doi: 10.1371/journal.pone.0194594
pubmed: 29617441
pmcid: 5884516
Adra N, Einhorn LH, Althouse SK et al (2018) Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol 29(1):209–214. https://doi.org/10.1093/annonc/mdx680
doi: 10.1093/annonc/mdx680
pubmed: 29045540
Chovanec M, Mardiak J, Mego M (2019) Immune mechanisms and possible immune therapy in testicular germ cell tumours. Andrology. Published online 6 June 2019:andr.12656. https://doi.org/10.1111/andr.12656
Bols B, Jensen L, Jensen A, Braendstrup O (2001) Immunopathology of in situ seminoma. Int J Exp Pathol 81(3):211–217. https://doi.org/10.1046/j.1365-2613.2000.00151.x
doi: 10.1046/j.1365-2613.2000.00151.x
Fankhauser CD, Sander S, Roth L et al (2018) Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. Br J Cancer 118(6):825–830. https://doi.org/10.1038/bjc.2017.467
doi: 10.1038/bjc.2017.467
pubmed: 29485982
pmcid: 5877429
Svetlovska D, Miskovska V, Cholujova D, et al (2017) Plasma cytokines correlated with disease characteristics, progression-free survival, and overall survival in testicular germ-cell tumor patients. Clin Genitourin Cancer 15(3):411–416.e2. https://doi.org/10.1016/j.clgc.2017.01.027
Mital P, Hinton BT, Dufour JM (2011) The blood-testis and blood-epididymis barriers are more than just their tight junctions1. Biol Reprod 84(5):851–858. https://doi.org/10.1095/biolreprod.110.087452
doi: 10.1095/biolreprod.110.087452
pubmed: 21209417
pmcid: 4574632
Rigau V, Zouaoui S, Mathieu-Daudé H et al (2011) French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 21(6):633–644. https://doi.org/10.1111/j.1750-3639.2011.00491.x
doi: 10.1111/j.1750-3639.2011.00491.x
pubmed: 21554472
Mottolese C, Szathmari A, Beuriat PA (2015) Incidence of pineal tumours. A review of the literature. Neurochirurgie 61(2–3):65–69. https://doi.org/10.1016/j.neuchi.2014.01.005
doi: 10.1016/j.neuchi.2014.01.005
pubmed: 25113513
DeGirolami U, Schmidek H (1973) Clinicopathological study of 53 tumors of the pineal region. J Neurosurg 39(4):455–462. https://doi.org/10.3171/jns.1973.39.4.0455
doi: 10.3171/jns.1973.39.4.0455
pubmed: 4730334
Shibui S, Nomura K (2009) Statistical analysis of pineal tumors based on the data of brain tumor registry of Japan. In: Progress in neurological surgery, vol. 23. KARGER, pp 1–11. https://doi.org/10.1159/000210049
Liu APY, Harreld JH, Jacola LM et al (2018) Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis. Acta Neuropathol Commun 6(1):101. https://doi.org/10.1186/s40478-018-0602-5
doi: 10.1186/s40478-018-0602-5
pubmed: 30253793
pmcid: 6154813
Lapras C, Bognar L, Turjman F et al (1994) Tectal plate gliomas. Part I: microsurgery of the tectal plate gliomas. Acta Neurochir 126(2–4):76–83. https://doi.org/10.1007/BF01476414
doi: 10.1007/BF01476414
pubmed: 8042559
Lassman AB (2015) Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? CNS Oncol 4(5):341–346. https://doi.org/10.2217/cns.15.36
doi: 10.2217/cns.15.36
pubmed: 26544062
pmcid: 6082332
Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10(15):4933–4938. https://doi.org/10.1158/1078-0432.CCR-04-0392
doi: 10.1158/1078-0432.CCR-04-0392
pubmed: 15297393
Pope WB, Prins RM, Thomas MA et al (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro-Oncol 107(1):197–205. https://doi.org/10.1007/s11060-011-0737-8
doi: 10.1007/s11060-011-0737-8
Lassaletta A, Zapotocky M, Mistry M et al (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35(25):2934–2941. https://doi.org/10.1200/JCO.2016.71.8726
doi: 10.1200/JCO.2016.71.8726
pubmed: 28727518
pmcid: 5791837
Becker AP, Scapulatempo-Neto C, Carloni AC et al (2015) KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol 74(7):743–754. https://doi.org/10.1097/NEN.0000000000000213
doi: 10.1097/NEN.0000000000000213
pubmed: 26083571
Phase II Pediatric study with dabrafenib in combination with Trametinib in patients With HGG and LGG – Full Text View. ClinicalTrials.gov . https://clinicaltrials.gov/ct2/show/NCT02684058
Hambardzumyan D, Gutmann DH, Kettenmann H (2015) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19(1):20–27. https://doi.org/10.1038/nn.4185
doi: 10.1038/nn.4185
Badie B, Schartner J (2001) Role of microglia in glioma biology. Microsc Res Tech 54(2):106–113. https://doi.org/10.1002/jemt.1125
doi: 10.1002/jemt.1125
pubmed: 11455617
Bowman RL, Klemm F, Akkari L et al (2016) Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep 17(9):2445–2459. https://doi.org/10.1016/j.celrep.2016.10.052
doi: 10.1016/j.celrep.2016.10.052
pubmed: 27840052
pmcid: 5450644
Varol C, Sagi I (2018) Phagocyte –extracellular matrix crosstalk empowers tumor development and dissemination. FEBS J 285(4):734–751. https://doi.org/10.1111/febs.14317
doi: 10.1111/febs.14317
pubmed: 29106767
Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19(12):3165–3175. https://doi.org/10.1158/1078-0432.CCR-12-3314
doi: 10.1158/1078-0432.CCR-12-3314
pubmed: 23613317
pmcid: 3742575
Ellert-Miklaszewska A, Wisniewski P, Kijewska M et al (2016) Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. Oncogene 35(50):6366–6377. https://doi.org/10.1038/onc.2016.55
doi: 10.1038/onc.2016.55
pubmed: 27041573
Zhou W, Ke SQ, Huang Z et al (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 17(2):170–182. https://doi.org/10.1038/ncb3090
doi: 10.1038/ncb3090
pubmed: 25580734
pmcid: 4312504
Butowski N, Colman H, De Groot JF et al (2016) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy foundation early phase clinical trials consortium phase II study. Neuro-Oncology 18(4):557–564. https://doi.org/10.1093/neuonc/nov245
doi: 10.1093/neuonc/nov245
pubmed: 26449250
Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100–1108. https://doi.org/10.1016/S1470-2045(14)70379-1
doi: 10.1016/S1470-2045(14)70379-1
pubmed: 25163906
Law M, Young RJ, Babb JS et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247(2):490–498. https://doi.org/10.1148/radiol.2472070898
doi: 10.1148/radiol.2472070898
pubmed: 18349315
Langlois B, Saupe F, Rupp T et al (2014) AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. Oncotarget 5(21):10529–10545. https://doi.org/10.18632/oncotarget.2470
doi: 10.18632/oncotarget.2470
pubmed: 25301723
pmcid: 4279391
Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. https://doi.org/10.1056/NEJMoa1308345
doi: 10.1056/NEJMoa1308345
pubmed: 24552318
Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20(1):110–119. https://doi.org/10.1016/S1470-2045(18)30675-2
doi: 10.1016/S1470-2045(18)30675-2
pubmed: 30522967
Griveau A, Seano G, Shelton SJ, et al (2018) A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment. Cancer Cell 33(5):874–889.e7. https://doi.org/10.1016/j.ccell.2018.03.020
Sun X, Ma X, Wang J et al (2017) Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. Oncotarget 8(22). https://doi.org/10.18632/oncotarget.16661
Zhu Y, Zhang X, Qi L et al (2016) HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget 7(12):14429–14440. https://doi.org/10.18632/oncotarget.7418
doi: 10.18632/oncotarget.7418
pubmed: 26894862
pmcid: 4924726
Cui X, Morales RTT, Qian W et al (2018) Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. Biomaterials 161:164–178. https://doi.org/10.1016/j.biomaterials.2018.01.053
doi: 10.1016/j.biomaterials.2018.01.053
pubmed: 29421553
pmcid: 8059366
Rymo SF, Gerhardt H, Sand FW, Lang R, Uv A, Betsholtz C (2011) A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures. PLoS ONE 6(1):e15846. https://doi.org/10.1371/journal.pone.0015846
doi: 10.1371/journal.pone.0015846
pubmed: 21264342
pmcid: 3018482
Bekaert L, Valable S, Lechapt-Zalcman E et al (2017) [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging 44(8):1383–1392. https://doi.org/10.1007/s00259-017-3677-5
doi: 10.1007/s00259-017-3677-5
pubmed: 28315948
Zagzag D, Lukyanov Y, Lan L et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Investig 86(12):1221–1232. https://doi.org/10.1038/labinvest.3700482
doi: 10.1038/labinvest.3700482
pubmed: 17075581
Chia K, Mazzolini J, Mione M, Sieger D (2018) Tumor initiating cells induce cxcr4- mediated infiltration of pro-tumoral macrophages into the brain. elife 7. https://doi.org/10.7554/eLife.31918
Mercurio L, Ajmone-Cat MA, Cecchetti S et al (2016) Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res 35(1):55. https://doi.org/10.1186/s13046-016-0326-y
doi: 10.1186/s13046-016-0326-y
pubmed: 27015814
pmcid: 4807593
Man J, Yu X, Huang H, et al (2018) Hypoxic induction of Vasorin regulates Notch1 turnover to maintain glioma stem-like cells. Cell Stem Cell 22(1):104–118.e6. https://doi.org/10.1016/j.stem.2017.10.005
Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA (2016) Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. Oncotarget 7(47):77457–77467. https://doi.org/10.18632/oncotarget.12681
doi: 10.18632/oncotarget.12681
pubmed: 27764809
pmcid: 5340227
Liu H, Xie Y, Zhang Y et al (2017) Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo−/radio-therapy for glioma. Biomaterials 121:130–143. https://doi.org/10.1016/j.biomaterials.2017.01.001
doi: 10.1016/j.biomaterials.2017.01.001
pubmed: 28088075
Brown CE, Alizadeh D, Starr R et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375(26):2561–2569. https://doi.org/10.1056/NEJMoa1610497
doi: 10.1056/NEJMoa1610497
pubmed: 28029927
pmcid: 5390684
Reardon DA, Omuro A, Brandes AA, et al (2017) OS10.3 Randomized phase 3 study evaluating the efficacy and safety of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: checkmate 143. Neuro-Oncology 19(suppl_3): iii21–iii21. https://doi.org/10.1093/neuonc/nox036.071
Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X
doi: 10.1016/S1470-2045(17)30517-X
pubmed: 28844499
McGranahan T, Therkelsen KE, Ahmad S, Nagpal S (2019) Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options in Oncol 20(3):24. https://doi.org/10.1007/s11864-019-0619-4
doi: 10.1007/s11864-019-0619-4
Hui CY, Rudra S, Ma S, Campian JL, Huang J (2019) Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients. J Neuro-Oncol 143(1):129–136. https://doi.org/10.1007/s11060-019-03146-7
doi: 10.1007/s11060-019-03146-7
Zadora P, Dabrowski W, Czarko K et al (2015) Preoperative neutrophil–lymphocyte count ratio helps predict the grade of glial tumor – a pilot study. Neurol Neurochir Pol 49(1):41–44. https://doi.org/10.1016/j.pjnns.2014.12.006
doi: 10.1016/j.pjnns.2014.12.006
pubmed: 25666772
Sayour EJ, McLendon P, McLendon R et al (2015) Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64(4):419–427. https://doi.org/10.1007/s00262-014-1651-7
doi: 10.1007/s00262-014-1651-7
pubmed: 25555571
pmcid: 4774199
Lowther DE, Goods BA, Lucca LE et al (2016) PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 1(5). https://doi.org/10.1172/jci.insight.85935
Woroniecka K, Chongsathidkiet P, Rhodin K et al (2018) T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 24(17):4175–4186. https://doi.org/10.1158/1078-0432.CCR-17-1846
doi: 10.1158/1078-0432.CCR-17-1846
pubmed: 29437767
pmcid: 6081269
Domenis R, Cesselli D, Toffoletto B et al (2017) Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells. PLOS ONE 12(1):e0169932. https://doi.org/10.1371/journal.pone.0169932
doi: 10.1371/journal.pone.0169932
pubmed: 28107450
pmcid: 5249124
Chang AL, Miska J, Wainwright DA et al (2016) CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res 76(19):5671–5682. https://doi.org/10.1158/0008-5472.CAN-16-0144
doi: 10.1158/0008-5472.CAN-16-0144
pubmed: 27530322
pmcid: 5050119
Poon CC, Gordon PMK, Liu K et al (2019) Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma. Oncotarget 10(33):3129–3143. https://doi.org/10.18632/oncotarget.26863
doi: 10.18632/oncotarget.26863
pubmed: 31139325
pmcid: 6517100
Berghoff AS, Kiesel B, Widhalm G et al (2017) Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology 19(11):1460–1468. https://doi.org/10.1093/neuonc/nox054
doi: 10.1093/neuonc/nox054
pubmed: 28531337
pmcid: 5737620
Venteicher AS, Tirosh I, Hebert C et al (2017) Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355(6332):eaai8478. https://doi.org/10.1126/science.aai8478
doi: 10.1126/science.aai8478
pubmed: 28360267
pmcid: 5519096
Jones TA, Jeyapalan JN, Forshew T et al (2015) Molecular analysis of pediatric brain tumors identifies microRNAs in pilocytic astrocytomas that target the MAPK and NF-κB pathways. Acta Neuropathol Commun 3(1):86. https://doi.org/10.1186/s40478-015-0266-3
doi: 10.1186/s40478-015-0266-3
pubmed: 26682910
pmcid: 4683939
Chen R, Keoni C, Waker CA, Lober RM, Chen Y-H, Gutmann DH (2019) KIAA1549-BRAF expression establishes a permissive tumor microenvironment through NFκB-mediated CCL2 production. Neoplasia 21(1):52–60. https://doi.org/10.1016/j.neo.2018.11.007
doi: 10.1016/j.neo.2018.11.007
pubmed: 30504064
Gilbert AR, Zaky W, Gokden M et al (2018) Extending the Neuroanatomic territory of diffuse midline glioma, K27M mutant: pineal region origin. Pediatr Neurosurg 53(1):59–63. https://doi.org/10.1159/000481513
doi: 10.1159/000481513
pubmed: 29131126
D’Amico RS, Zanazzi G, Wu P, Canoll P, Bruce JN (2018) Pineal region glioblastomas display features of diffuse midline and non-midline gliomas. J Neuro-Oncol 140(1):63–73. https://doi.org/10.1007/s11060-018-2931-4
doi: 10.1007/s11060-018-2931-4
Louis DN, Giannini C, Capper D et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135(4):639–642. https://doi.org/10.1007/s00401-018-1826-y
doi: 10.1007/s00401-018-1826-y
pubmed: 29497819
Lin GL, Nagaraja S, Filbin MG, Suvà ML, Vogel H, Monje M (2018) Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun 6(1):51. https://doi.org/10.1186/s40478-018-0553-x
doi: 10.1186/s40478-018-0553-x
pubmed: 29954445
pmcid: 6022714
Lieberman NAP, DeGolier K, Kovar HM et al (2019) Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro-Oncology 21(1):83–94. https://doi.org/10.1093/neuonc/noy145
doi: 10.1093/neuonc/noy145
pubmed: 30169876
Lee JH, Lee JE, Kahng JY et al (2018) Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560(7717):243–247. https://doi.org/10.1038/s41586-018-0389-3
doi: 10.1038/s41586-018-0389-3
pubmed: 30069053
Denicolaï E, Tabouret E, Colin C et al (2016) Molecular heterogeneity of glioblastomas: does location matter? Oncotarget 7(1). https://doi.org/10.18632/oncotarget.6433
Engwer C, Hillen T, Knappitsch M, Surulescu C (2015) Glioma follow white matter tracts: a multiscale DTI-based model. J Math Biol 71(3):551–582. https://doi.org/10.1007/s00285-014-0822-7
doi: 10.1007/s00285-014-0822-7
pubmed: 25212910
Wang J, Xu S-L, Duan J-J et al (2019) Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1–SOX2 positive-feedback loop. Nat Neurosci 22(1):91–105. https://doi.org/10.1038/s41593-018-0285-z
doi: 10.1038/s41593-018-0285-z
pubmed: 30559479
Stowe HB, Miller CR, Wu J, Randazzo DM, Ju AW (2017) Pineal region glioblastoma, a case report and literature review. Front Oncol 7. https://doi.org/10.3389/fonc.2017.00123
Birbrair A, Zhang T, Wang Z-M et al (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 307(1):C25–C38. https://doi.org/10.1152/ajpcell.00084.2014
doi: 10.1152/ajpcell.00084.2014
pubmed: 24788248
pmcid: 4080181
Prazeres PHDM, Leonel C, Silva WN, et al (2020) Ablation of sensory nerves favours melanoma progression. J Cell Mol Med. Published online 20 July 2020. https://doi.org/10.1111/jcmm.15381